Intervention not reported
Adverse events (total): · adults aged ≥ 18 years with a diagnosis of glenohumeral osteoarthritis who have not responded to non‐operative treatments
It is very uncertain whether the intervention changes adverse events (total): (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events (serious ‐ resulting in hospitalisation or death) · adults aged ≥ 18 years with a diagnosis of glenohumeral osteoarthritis who have not responded to non‐operative treatments
1 finding from 1 review
Intervention not reported
Revision, re‐operation, or treatment failure · adults aged ≥ 18 years with a diagnosis of glenohumeral osteoarthritis who have not responded to non‐operative treatments
It is very uncertain whether the intervention changes revision, re‐operation, or treatment failure (very low certainty).
1 finding from 1 review
Intervention not reported
Change in urinary GAG excretion from baseline · adults and children with mucopolysaccharidosis I
1 finding from 1 review
Intervention not reported
Mean percentage change from baseline in FVC (% predicted) · adults and children with mucopolysaccharidosis I
1 finding from 1 review
Intervention not reported
Mean change from baseline in 6MWT (metres) · adults and children with mucopolysaccharidosis I
1 finding from 1 review
Intervention not reported
Infusion‐related reactions (number of participants with one or more reaction) · adults and children with mucopolysaccharidosis I
The intervention showed no clear difference in infusion‐related reactions (number of participants with one or more… (low certainty).
1 finding from 1 review
Intervention not reported
Antibody production: number of participants developing IgG antibodies · adults and children with mucopolysaccharidosis I
It is very uncertain whether the intervention changes antibody production: number of participants developing IgG antibodies (very low certainty).
1 finding from 1 review
Intervention not reported
Quality of life · adults and children with mucopolysaccharidosis I
1 finding from 1 review
Intervention not reported
Mortality: number of deaths · adults and children with mucopolysaccharidosis I
1 finding from 1 review
Live birth rate – euthyroid women with anti‐TPO antibodies · subfertile women with euthyroid autoimmune thyroid disease or subclinical hypothyroidism
Thyroxine showed no clear difference in live birth rate – euthyroid women with anti‐TPO antibodies compared with placebo or no treatment (low certainty).
1 finding from 1 review
Adverse events including maternal pregnancy complications, foetal complications and adverse effects of thyroxine · subfertile women with euthyroid autoimmune thyroid disease or subclinical hypothyroidism
Thyroxine led to lower adverse events including maternal pregnancy complications, foetal… compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Miscarriage – anti‐TPO antibodies · subfertile women with euthyroid autoimmune thyroid disease or subclinical hypothyroidism
Thyroxine showed no clear difference in miscarriage – anti‐TPO antibodies compared with placebo or no treatment (low certainty).
1 finding from 1 review
Intervention not reported
Smoking cessation at 6+ months · people who smoke cigarettes
The intervention leads to higher smoking cessation at 6+ months (high certainty).
1 finding from 1 review
Intervention not reported
Cardiac function · infantile‐onset Pompe disease
1 finding from 1 review
Intervention not reported
Time to ventilation · infantile‐onset Pompe disease
1 finding from 1 review
Intervention not reported
Survival · infantile‐onset Pompe disease
1 finding from 1 review
Intervention not reported
Motor development · infantile‐onset Pompe disease
1 finding from 1 review
Intervention not reported
Quality of life · infantile‐onset Pompe disease
1 finding from 1 review
Intervention not reported
Infusion‐related events · infantile‐onset Pompe disease
The intervention showed no clear difference in infusion‐related events (low certainty).
1 finding from 1 review